PMA supplement
BP020066 S003: Vironostika HIV-1 Plus O Microelisa System
FDA PMA supplement · 30-Day Notice · BioMerieux, Inc.
Key facts
| Original PMA | BP020066 |
|---|---|
| Supplement number | S003 |
| Supplement type | 30-Day Notice |
| Trade name | Vironostika HIV-1 Plus O Microelisa System |
| Generic name | Hiv detection test |
| Applicant | BioMerieux, Inc. |
| Product code | MZF |
| Received date | Jan 14, 2004 |
| Decision date | Feb 12, 2004 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: